80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

FOR IMMEDIATE RELEASE

QT Vascular Announces Approval and Launch of GliderXtreme™ in China

- Product was recently featured at the prestigious China Endovascular Course in Beijing
- Initial product shipment made to distributor, Weigao, with additional shipments pending
- Launch of GliderXtreme™ PTA catheter will allow Group to leverage on growing ageing population in China

Singapore, 20 January 2015 – Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has today started shipments of the GliderXtreme™ PTA catheter to China. The initial shipment of the GliderXtreme™ PTA catheter was made via Shandong Weigao Group Medical Polymer Co Ltd ("Weigao").

GliderXtreme™ is designed for the treatment of peripheral arterial blockages. Its innovative features include a low-profile nitinol shaft and a proprietary "slide-lock" design. Together these features produce exceptional push force delivered at the tip of the catheter, providing physicians with the confidence needed to begin and finish cases including those involving long and diffuse lesions.

The Group previously announced on 17 December 2014 that its products, including the GliderXtreme™ PTA catheter, were recently featured at the China Endovascular Course (CEC) in Beijing. Speaking on behalf of the Group at CEC on 29 November 2014, Mr. Christopher Haig, Vice President of Corporate Development, delivered three presentations titled *Overview of a New PTA Balloon: GliderXtreme™, A New Treatment Paradigm for Peripheral Disease: The Chocolate® PTA Balloon and View to the Future: Drug-Coated Chocolate® Touch*. QT Vascular is constantly investing in the development of cutting edge technologies and the unique value of the Group's technology is validated via the launch of the GliderXtreme™ PTA catheter in China.

"The medical community across Asia is recognizing the growing incidence of peripheral arterial disease that threatens the health and well-being of millions of patients," stated Dr. Eitan Konstantino PhD, the Company's Chief Executive Officer. **"GliderXtreme™ was designed to maintain push force even in long balloons. We are proud to work closely with our partner, Weigao, to commercialize this device in China."**

"GliderXtreme™ is a highly differentiated PTA balloon that will enable Chinese physicians to treat complex lesions both above and below the knee," explained Mr. Sun Feng Wei, General Manager of Weigao Medical Devices, Ltd.. **"We are looking forward to working closely with TriReme Medical, LLC, the Company's wholly-owned subsidiary, to introduce this product as well as their other products into the growing Chinese marketplace."**

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

- End –

About QT Vascular Ltd.
QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

About Weigao
Based in Weihai, China and publicly traded on the Hong Kong Stock Exchange (Stock Code: 1066), Weigao manufactures and sells over 100 types of products, including disposable medical consumables, orthopedic materials and tools, medical needles, blood purification consumables, and interventional cardiology devices. It maintains a vast distribution network of 24 regional sales offices, 30 customer service centers, 100 municipal representatives, and 1200 sales representatives. It sells to over 2700 hospitals, 400 blood stations, and over 1500 distribution/trading partners across China.

About Peripheral Artery Disease
Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide[1].

For more information, please refer to: http://www.qtvascular.com/
References:
[1] "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.

Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd
Kamal SAMUEL, kamal@financialpr.com.sg
Mark LIN, marklin@financialpr.com.sg
Tel: (65) 6438 2990 Fax: (65) 6438 0064

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.